Gilead’s Remdesivir is first coronavirus drug to get US Food and Drug Administration approval
- Antiviral therapy has already been widely used in hospitalised Covid-19 patients after being granted emergency-use authorisation earlier this year
- Remdesivir was given to Trump when US president was diagnosed with virus earlier this month
The US Food and Drug Administration approved Gilead Sciences’ antiviral therapy remdesivir on Thursday, making it the first drug to obtain formal clearance for treating the coronavirus.
Regulators had granted an emergency-use authorisation for remdesivir earlier this year, and since then the drug has become a widely used therapy in hospitalised Covid-19 patients. It was given to US President Donald Trump this month when he was diagnosed with the virus.
The approval of remdesivir, sold under the brand name Veklury, will allow Gilead to market the drug and talk about its benefits to doctors, nurses, and patients. That could help solidify its position as a go-to medicine for Covid-19 patients even as other drugs for the disease begin to reach the market.
“Veklury is now the first and only approved Covid-19 treatment in the United States,” Gilead said in a statement. While the drug was in short supply initially, Gilead said that the medicine is now widely available in hospitals across the country as manufacturing capacity has rapidly expanded.
The drug has not been proven to reduce deaths from Covid-19. In a World Health Organization trial, the medicine failed to reduce fatalities, according to preliminary results that were posted on preprint servers last week.
Gilead has criticised the WHO study. In a letter posted on the company’s website, Chief Medical Officer Merdad Parsey said the findings do not negate other results.
Shares of Gilead gained 4.1 per cent in trading after the close of regular market hours on Thursday. Analysts estimate that remdesivir will have sales of US$2.17 billion this year, according to 13 surveyed by Bloomberg.
Firm questions WHO study that found remdesivir has little effect on virus
The company said in June that it will charge US hospitals roughly US$3,120 for most patients who need remdesivir.
The approval is based on a US government-sponsored trial involving more than 1,000 hospitalised coronavirus patients that found that those who received the drug recovered about five days faster than those who got a placebo.
The overall side-effect rate was similar to the placebo in the government study. The most common side effects are nausea and elevated liver enzymes, according to the product’s label.
